CDK8 and non-small cell lung carcinoma: The competitiveness of RFC4 stems from its approximately 5-fold higher binding affinity to NICD1 compared to CDK8, and the augmented expression level of RFC4 in NSCLC tissues further amplifies its competitive binding to NICD1 over CDK8.